SAGE Therapeutics Inc: A Promising Q4 2024 Earnings Call

SAGE Therapeutics Inc (SAGE) reported its Q4 and full-year 2024 financial results on February 11, 2025, highlighting strong growth in its postpartum depression treatment, ZURZUVAE. The company achieved nearly 2,500 shipments in Q4 2024, a 21% increase from Q3, with over 6,600 prescriptions delivered throughout 2024. ZURZUVAE collaboration revenue was $11.4 million in Q4 2024 and $36.1 million for the year ended December 31, 2024, representing 50% of the net revenues recorded by Biogen.

SAGE Therapeutics maintained a strong financial position with $504 million in cash and equivalents, expecting runway through mid-2027. The company's strategic initiatives, including joint sales force expansions, planned digital marketing campaigns, and increased disease state awareness efforts, contributed to ZURZUVAE's commercial momentum. Greater than 95% of Commercial and Medicaid lives are covered or have a path to coverage, with OBGYNs accounting for almost 80% of all prescriptions. The company saw a strong repeat rate in 2024, with about 60% of targeted HCPs writing repeat prescriptions after prescribing ZURZUVAE, and more than 70% of ZURZUVAE patients receiving the drug as their first new treatment for PPD.

SAGE Therapeutics' Q4 2024 earnings call demonstrated the company's commitment to helping more women with postpartum depression receive treatment with ZURZUVAE, advancing its focused R&D efforts, and creating near and long-term value for Sage and its shareholders. The company's strategic initiatives, strong financial position, and promising Q4 results position SAGE Therapeutics for potential accelerated growth in 2025.